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Abstract In the wild-type tachykinin NK3A receptor histidyl
residues are present at two positions in TM-V, V:01 and V:05, at
which Zn2+ functions as an antagonist in NK1 and U-opioid
receptors with engineered metal-ion sites. Surprisingly, in the
NK3A receptor Zn2+ instead increased the binding of the agonist
125I-[MePhe7]neurokinin B to 150%. [MePhe7]neurokinin B
bound to the NK3A receptor in a two-component mode of which
Zn2+ eliminated the subnanomolar binding mode but induced a
higher binding capacity of the nanomolar binding mode. Signal
transduction was not induced by ZnCl2 but 10 WM ZnCl2
enhanced the effect of neurokinin B. Ala-substitution of HisV:01
eliminated the enhancing effect of Zn2+ on peptide binding. It is
concluded that physiological concentrations of Zn2+ have a
positive modulatory effect on the binding and function of
neurokinin B on the NK3A receptor through a bis-His site in
TM-V.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
In mammals, there are three types of receptors for the ho-
mologous tachykinin neuropeptides: substance P, neurokinin
A (NKA), and neurokinin B (NKB) [1,2]. The NK1 receptor,
which is found both centrally and peripherally binds prefer-
entially substance P but also acts as a high a⁄nity receptor
for the two other neurokinins, NKA and NKB [3]. The NK2
receptor binds preferentially NKA and is found almost exclu-
sively in the periphery [1,2]. In contrast, the two NK3 receptor
subtypes, which are selective for NKB, are almost exclusively
expressed in the central nervous system, especially the cerebral
cortex and hippocampus [1,2,4]. It was originally believed that
there was only one NK3 receptor type. However, recently Jim
Krause and coworkers discovered that an orphan receptor
which originally was suspected to be an opioid receptor [5]
in fact could be activated by nanomolar concentrations of
NKB [4]. Accordingly, it has been suggested that the two
highly homologous NKB receptors, which mainly di¡er in
the long N-terminal extension (see Fig. 1) should be called
NK3A and NK3B [3].
Previously we have engineered metal-ion binding sites into
other 7TM receptors by site directed mutagenesis. Initially
this was performed in the NK1 receptor by probing the bind-
ing site for a non-peptide antagonist systematically with his-
tidine substitutions. In this way the antagonist binding site
was both structurally and functionally converted into a high
a⁄nity zinc site [6]. The originally constructed tridentate met-
al-ion site, which consisted of two His residues located in an i
and i+4 position in TM-V and a single His residue located
across in TM-VI, could be moved to the U-opioid receptor
without loss of a⁄nity for Zn2 [7]. Arti¢cially introduced
metal-ion sites have subsequently been used as structural
and functional probes, which have provided important dis-
tance constraints in molecular models of 7TM receptors and
information about conformational changes occurring between
helices [8^10]. In all cases, the binding of the metal ion has
been antagonistic as it was blocking ligand binding and/or
inhibiting signal transduction [10].
An optimal location of two histidyl residues for binding
Zn2 is in an i and i+4 position in an K-helix [11]. In accord-
ance with this, Zn2 binds with single digit WM a⁄nity be-
tween histidyl residues introduced at position V:01 and V:05
both in the NK1 and the U-opioid receptor [6,7]. As shown in
Fig. 1, in both of the NK3 receptor subtypes histidyl residues
are located at these two positions in the wild-type receptor
proteins. Since zinc is stored and released from synaptic
vesicles in the brain, and since zinc concentration in the ex-
tracellular £uid accordingly is high and regulated [12^14], we
have studied here the e¡ect of Zn2 on ligand binding and
signal transduction in the NK3A receptor with and without
substitution of one of the two histidyl residues in TM-V.
Surprisingly, it is found that in the wild-type NK3A receptor
Zn2 enhances ligand binding in contrast to the blocking ef-
fect which is observed in all the receptors where this metal-ion
site has been arti¢cially introduced.
2. Materials and methods
2.1. Materials
NKB and [MePhe7]NKB were purchased from Peninsula (St. Hel-
ens, Merseyside, UK). The NK3A non-peptide antagonist, SR142,271,
was kindly provided by Drs. Xavier Edmons-Alt and Jean-Claude
BrelieØre (Sano¢ Recherche, Montpellier, France) [15]. Pfu polymerase
was from Stratagene (La Jolla, CA, USA). AG 1-X8 anion-exchange
resin was from Bio-Rad (Hercules, CA, USA). [3H]myo-inositol (PT6-
271); Bolton-Hunter reagent, speci¢c activity 2000 Ci/mmol; and
Thermo Sequenase £uorescent labeled primer cycle sequencing kit
with 7-deaza-dGTP were from Amersham (Little Chalfont, UK).
2.2. Construction of the [H244A]NK3A mutant receptor
The cDNA encoding the wild-type human NK3A receptor gener-
ously supplied by Dr. Cathrine Strader [16] was cloned into the eu-
karyotic expression vector pTEJ-8 [17]. The mutation was constructed
by polymerase chain reaction (PCR) using the overlap extension
method [18] and pfu polymerase according to the instruction of the
manufacturer. The PCR product was digested with appropriate re-
striction endonucleases, puri¢ed, and cloned into the pTEJ8-NK3A.
The mutation was veri¢ed by restriction endonuclease mapping and
subsequent DNA sequence analysis using the Thermo Sequenase £u-
orescent labeled primer cycle sequencing kit with 7-deaza-dGTP on an
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Alfexpress DNA sequencer according to manufacturers’ instructions
(Pharmacia Biotech, Uppsala, Sweden).
2.3. Transfections and tissue culture
COS-7 cells were grown in Dulbecco’s Modi¢ed Eagle Medium
1885 supplemented with 10% fetal calf serum, 2 mM glutamine and
0.01 mg/ml gentamicin. The expression plasmids containing the
cDNAs encoding the wild-type or mutant receptors were transiently
expressed after transfection by the calcium phosphate precipitation
method.
2.4. Binding experiments
Monoiodinated 125I-[MePhe7]NKB (NEX285) was purchased from
New England Nuclear. Transfected COS-7 cells were transferred to
culture plates one day after transfection. The number of cells per well,
20 000, was determined by the apparent expression e⁄ciency of the
individual clones aiming at 5^10% binding of the added radioligand.
Two days after transfection, cells were assayed by competition binding
for 3 h at 4‡C using 35 pM 125I-[MePhe7]NKB plus variable amounts
of unlabeled ligand in 0.5 ml of a 50 mM Tris-HCl bu¡er, pH 7.4,
supplemented with 150 mM NaCl, 5 mM MnCl2, 0.1% (w/v) bovine
serum albumin, 40 Wg/ml bacitracin. Non-speci¢c binding was deter-
mined as the binding in the presence of 1 WM [MePhe7]NKB. Deter-
minations were made in triplicate.
2.5. Phosphatidylinositol assay
One day after transfection COS-7 cells (0.3U106 cells/well) were
incubated for 24 h with 5 WCi of [3H]-myo-inositol in 0.5 ml inosi-
tol-free Dulbecco’s 1885 medium supplemented with 10% fetal calf
serum, 2 mM glutamine and 0.01 mg/ml gentamicin per well. Cells
were washed twice in 20 mM HEPES, pH 7.4, supplemented with 140
mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10 mM glucose,
0.05% (w/v) bovine serum albumin, and were incubated in 0.5 ml PI-
bu¡er supplemented with 10 mM LiCl at 37‡C for 30 min. After
stimulation for 20 min at 37‡C with increasing concentration of
NKB with or without added ZnCl2, or stimulation with ZnCl2 with
or without added NKB, the cells were extracted with 10% ice-cold
perchloric acid followed by incubation on ice for 30 min. The result-
ing supernatant was neutralized with KOH in HEPES bu¡er, and the
generated [3H]inositol phosphates were puri¢ed on Bio-Rad AG 1-X8
anion-exchange resin [19]. Determinations were made in triplicate.
2.6. Calculations
IC50 and EC50 values were determined by non-linear regression
using the Inplot 4.0 software (GraphPad Software, San Diego, CA,
USA). Kd and Bmax values were calculated from competition binding
experiments with 10^12 di¡erent concentrations of cold ligand and
using the equation Kd = IC503L and Bmax = Bo(1+(Kd/L)). Ki values
were calculated using the equation Ki = IC50/(1+L/Kd) [20]. The ho-
mologous competition binding experiments with [MePhe7]NKB in the
presence of various concentrations of ZnCl2 were further analyzed
based on the two-component binding mode observed in the absence
of the metal-ion using Inplot. These calculations were performed by
holding the IC50 of the high a⁄nity binding mode constant (although
the binding capacity of this binding mode was gradually reduced in
response to the increasing concentrations of ZnCl2) and calculating
the percentage distribution between the high a⁄nity and the low af-
¢nity state as well as the a⁄nity of the low a⁄nity state.
3. Results
In mutated versions of both the NK1 receptor and the U-
opioid receptor in which histidyl residues are introduced at
positions V:01 and V:05, Zn2 in concentrations from 1036 to
1034 M compete in a mono-component, dose-dependent man-
ner for binding with radioactive ligands (dashed curves in Fig.
2A) [21,22]. In contrast, in the NK3A receptor, where histidyl
residues are located at these two positions already in the wild-
type receptor (Fig. 1), Zn2 in£uenced ligand binding in a
biphasic manner. In concentrations from 1036 to 1035 M
ZnCl2 increased the binding of 125I-[MePhe7]NKB whereas
concentrations from 1034 to 1032 M blocked ligand binding
(Fig. 2A). A maximum of 140 þ 4% binding of 125I-[MePhe7]-
NKB was found with 1035 M of ZnCl2 (N = 24). The agonist-
enhancing e¡ect of ZnCl2 was conceivably mediated through
Zn2 binding to the bis-His site at the extracellular end of
transmembrane segment V (Fig. 1) since the enhancing e¡ect
was not observed in the mutant receptor, where one of these
histidyl residues had been mutated into an alanine,
[H244A]NK3A (Fig. 2B). In the mutant receptor, only the
ligand-blocking e¡ect at high Zn2 concentrations was ob-
served just as it is observed in several other wild-type recep-
tors at similar high concentrations [6,7].
Competition binding experiments performed with [MePhe7]-
NKB at various Zn2 concentrations con¢rmed the enhancing
e¡ect of the metal ion on peptide binding (Fig. 3A). An in-
crease in binding capacity from 194 þ 17 in the absence to
486 þ 64 fmol/105 cells in the presence of 1034:5 M ZnCl2
was found for the wild-type receptor, whereas no change in
binding capacity was observed in the [H244A] mutant form of
the NK3A receptor (Table 1). More detailed analysis of the
binding curves revealed that [MePhe7]NKB in the absence of
Zn2 interacted with the wild-type NK3A receptor in a two-
component fashion with 62 þ 5% being bound in a very high
a⁄nity mode (Ki = 0.20 þ 0.03 nM) and 38% being bound in a
nanomolar mode (Ki = 3.2 þ 0.6 nM), calculated by individual
analysis of 24 experiments (Fig. 3B). Surprisingly, while Zn2
increased the total amount of bound 125I-[MePhe7]NKB (Fig.
3A, Table 1) the metal ion at the same time in a dose-depend-
ent manner eliminated the binding of the radioactive peptide
ligand to the very high a⁄nity site (table inserted in Fig. 3B).
This elimination of the very high a⁄nity state was also re-
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Table 1
Competition binding experiments for the peptide agonist [MePhe7]NKB and for the non-peptide antagonist SR142,271 in the wild-type human
NK3A receptor and in the [H244A] mutant form of this
NK3A ZnCl2 (M) Bmax (fmol/105 cell) [MePhe7]NKB SR142,271
Ki (nM) (n) Hill Ki (nM) (n) Hill
Wild type 0 194 þ 17 0.53 þ 0.06 (24) 30.71 þ 0.02 1.47 þ 0.16 (8) 31.19 þ 0.14
1036 234 þ 24 0.98 þ 0.14 (6) 30.77 þ 0.07 2.47 þ 0.34 (5) 31.27 þ 0.14
1035 449 þ 78 1.01 þ 0.18 (9) 30.91 þ 0.05 1.35 þ 0.17 (8) 31.12 þ 0.11
1034:5 486 þ 64 1.54 þ 0.20 (7) 31.12 þ 0.09 2.02 þ 0.18 (6) 31.30 þ 0.10
[H244A] 0 397 þ 49 1.15 þ 0.14 (4) 30.95 þ 0.08 0.94 þ 0.10 (5) 31.26 þ 0.13
1036 405 þ 80 1.56 þ 0.29 (5) 30.89 þ 0.04 0.80 þ 0.06 (3) 30.95 þ 0.03
1035 431 þ 91 1.62 þ 0.40 (5) 30.97 þ 0.12 0.93 þ 0.10 (3) 30.98 þ 0.18
1034:5 422 þ 100 1.72 þ 0.24 (5) 30.95 þ 0.09 0.82 þ 0.15 (3) 31.15 þ 0.09
The receptors were expressed transiently in COS-7 cells and competition binding experiments were performed as described in the text using
125I-[MePhe7]NKB.
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£ected in the gradual change in Hill coe⁄cient from 30.71
towards unity (Table 1). Thus, ZnCl2 eliminates the very high,
sub-nanomolar a⁄nity binding state of the NK3A receptor
while it increases the binding capacity of the nanomolar af-
¢nity state of the receptor.
The very high a⁄nity state of peptide binding was not
observed in the [H244A]NK3A receptor as 125I-[MePhe7]NKB
bound with an a⁄nity (Ki) of 1.15 nM in a mono-component
fashion with a Hill coe⁄cient of 30.95 (Table 1). Zn2 did
not a¡ect the binding a⁄nity and it did not a¡ect the binding
capacity for [MePhe7]NKB in the [H244A]NK3A receptor as
determined in competition binding experiments (Table 1).
The e¡ect of ZnCl2 on non-peptide antagonist binding was
tested with SR142,271 in competition binding experiments
against 125I-[MePhe7]NKB. Zn2 did not a¡ect the high a⁄n-
ity, mono-component binding of the non-peptide antagonist
neither in the wild-type nor in the mutant receptor (Table 1).
Dose-response curves for induction of phosphatidylinositol
turnover by NKB through the NK3A receptor performed in
the absence and in the presence of 1035 M ZnCl2 were almost
superimposable with an EC50 of 1.4 þ 0.4 nM and 1.1 þ 0.3
nM, respectively (Fig. 4A). However, when dose-response ex-
periments for ZnCl2 were performed in the presence of low,
sub-maximal doses of NKB, a small potentiating e¡ect of
1035 M Zn2 upon the signalling of NKB was revealed
(Fig. 4B).
4. Discussion
4.1. Positions V:01 and V:05 are located optimally for Zn2+
binding in 7TM receptors
Previously we have built histidyl residues into these two
positions in various 7TM receptors: the NK1 [6], the U-opioid
[7], the NK2 (M. Lucibello, M.M. Rosenkilde, B. Holst, S.A.
Hjorth and T.W. Schwartz, unpublished observation), and in
chemokine receptors (M.M. Rosenkilde, T.N. Kledal and
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Fig. 1. Serpentine and helical wheel diagram of the tachykinin NK3A receptor. The helical wheel diagram is built over the rhodopsin structure
[28] as interpreted by Baldwin [29] with TM-III as the central helix and in anti-clockwise orientation as viewed from outside the cell, which re-
cently has been probed experimentally [8]. Helix-helix interaction has been optimized on the basis of metal-ion site engineering [10]. Residues
which are conserved between the NK3A and NK3B receptors are shown in black on grey. However, of these conserved residues HisV:01
(His244) and HisV:05 (His248) are highlighted in white on black. The generic numbering system for residues in 7TM receptors with the helix
number in roman followed by the residue number in Latin separated by a ‘:’ is used here and in the text [29].
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T.W. Schwartz, unpublished observation). In all these cases
Zn2 at single digit WM concentrations inhibits the binding of
ligands and/or the signaling of the receptor (see for example
Fig. 2A). This e¡ect is not observed in the corresponding
wild-type receptors. The high a⁄nity binding of Zn2 to these
two histidyl residues and the fact that interhelical bis-His zinc
sites can be constructed from these positions in TM-V to
positions in TM-III and TM-VI [8,10] indicate that: (i) posi-
tions V:01 and V:05 in 7TM receptors are located in an K-
helical structure; (ii) these residues are facing inward towards
TM-III and VI; and (iii) side chains at these positions are
relatively freely accessible for ions in solution.
4.2. Zn2+ binds to the NK3A wild-type receptor with single
digit WM a⁄nity
The high a⁄nity Zn2 binding to the NK3A receptor can be
observed indirectly in the dose-dependent positive e¡ect of
low concentrations of the metal ion on the peptide binding
capacity (Fig. 3A, Table 1) and in the dose-dependent nega-
tive e¡ect of the metal ion on the very high a⁄nity binding
mode for the peptide (Fig. 3B). More than half of the very
high a⁄nity, subnanomolar binding sites for [MePhe7]NKB
are eliminated by 1035 M ZnCl2 (insert in Fig. 3B). This is an
e¡ect which is rather similar to that observed with ZnCl2 on,
for example, 125I-substance P binding in the mutant NK1
receptor in which two histidines were introduced in TM-V
(dashed curve in Fig. 2A).
The e¡ect of Zn2 binding to the NK3A receptor mimics the
e¡ect of mutating one of the two histidyl residues in TM-V at
least to a certain degree. Thus, both Zn2 binding and muta-
tion of HisV:01 (His244) eliminate the very high a⁄nity bind-
ing of [MePhe7]NKB. The location of HisV:01 (His244) at the
exterior part of the main ligand binding crevice suggests that
the imidazole side chain of HisV:01 (His244) could be more or
less directly involved in binding the peptide ligand. Impor-
tantly, however, the very high a⁄nity binding mode for
NKB does not appear to be necessary for activation of the
NK3A receptor since normal stimulation of phosphatidylino-
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Fig. 3. Competition binding curves for [MePhe7]NKB in the wild-
type NK3A receptor at various ZnCl2 concentrations. Panel A:
Binding of 125I-[MePhe7]NKB expressed as % of maximally bound
radioligand in the absence of ZnCl2 (a ^ a) and in the presence of
1036 M (R ^ R), 1035 M (O ^ O), and 1034:5 M (b ^ b) ZnCl2.
Panel B: Binding of 125I-[MePhe7]NKB expressed as % of maxi-
mally bound radioactive ligand in the presence of the indicated
ZnCl2 concentrations. The summarized binding curve (N = 24) for
[MePhe7]NKB in the absence of ZnCl2 had a Hill coe⁄cient of
30.7 and analysis based on a two-component binding mode gave a
very high (0.2 nM) and a high a⁄nity (2.0 nM) sites. In the inserted
table the relative distribution of these two a⁄nity sites in the ab-
sence and presence of ZnCl2 is shown. The summarized binding
curves for [MePhe7]NKB in the presence of ZnCl2 1035 and 1034:5
M were analyzed based on a two-component binding mode where
the a⁄nity of the very high a⁄nity site was kept constant at
0.2 nM.
Fig. 2. Dose-response curves for ZnCl2 on the binding of 125I-
[MePhe7]NKB to the human NK3A receptor. Binding experiments
were performed as whole cell binding on transiently transfected
COS-7 cells at 4‡C. Panel A shows binding experiments performed
in the wild-type NK3A receptor (b ^ b). For comparison the dose-
response curves for ZnCl2 against 125I-substance P binding in the
mutated NK1 receptor (long dashes) and against [3H]diprenorphine
binding in the mutated U-opioid receptor (short dashes) are shown.
In both cases two histidines were present at positions V:01 and
V:05, respectively [6,7]. Panel B shows binding experiments per-
formed in the [H244A]NK3A receptor (a ^ a) where HisV:01 had
been exchanged.
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sitol turnover is observed in the presence of 1035 M ZnCl2
(Fig. 4A). Under these circumstances, the very high a⁄nity
binding mode is basically eliminated (insert in Fig. 3B).
4.3. How does Zn2+ enhance agonist binding?
Since Zn2 eliminates one binding mode of the peptide
agonist, it could have been anticipated that the amount of
bound radioactive peptide would decrease. On the contrary,
an increase in bound peptide is observed. Thus it must be
concluded that the zinc ions stabilize the nanomolar a⁄nity
agonist binding state of the NK3A receptor, and that it con-
sequently is able to pull more receptors into this conforma-
tion. In this context it is important to recall that in 7TM
receptor systems the Bmax values calculated on the basis of
binding experiments performed with agonists are often lower
than those based on binding with radioactive antagonists [23].
This at least indicates that there is a potential to increase the
binding capacity for agonists. The actual conformational
change which is stabilized or induced by Zn2 is obviously
today unclear. However, the binding of the zinc ion between
HisV:01 and HisV:05 will very likely stabilize the helical
structure of the extracellular end of TM-V since these two
residues are located one helical pitch apart in the presumed
K-helical structure of the transmembrane segment. Cysteine
availability scanning experiments have indicated that the hel-
ical structure in this part of 7TM receptors can be rather
unstable [24].
4.4. Is the e¡ect of Zn2+ of physiological importance?
Zinc is rather abundant in the brain [12,13], where the
NK3A receptors are expressed. Importantly, a number of spe-
ci¢c metal-ion transporters ensure that zinc ions are stored in
synaptic vesicles, especially in glutaminergic neurons [13]. Zinc
ions have been described to modulate the glutaminergic trans-
mission both as positive and negative modulators. Thus, phys-
iological concentrations of Zn2 inhibit the NMDA receptor
function and potentiate the non-NMDA receptors [25^27].
The concentration of Zn2 in the synaptic cleft has been esti-
mated to reach more than 1034 M during stimulation [14]. If
this is correct, then the agonist enhancing phenomenon de-
scribed for Zn2 in the present study for the NK3A receptor
could very well be of physiological importance. It should be
noted that the two histidyl residues which constitute the met-
al-ion site in the NK3A receptor are conserved in the NK3B
receptor (Fig. 1) [4] ; it is therefore likely that Zn2 will bind
to this receptor with single digit WM a⁄nity also.
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